Loading company…
Orchard Therapeutics PLC, based in London, UK, develops ex vivo gene therapies for serious rare diseases.
Based in London, UK, and founded in 2015, Orchard Therapeutics PLC develops autologous ex vivo gene therapies, in which a patient's own blood stem cells are modified and transplanted back, for rare diseases. The company acquired GSK's rare disease gene therapy portfolio in 2018 and went public in October 2018 (Nasdaq: ORTX). In October 2023, Kyowa Kirin agreed to acquire Orchard Therapeutics PLC for approximately USD 387.40 million. Recorded stage: Public.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in